AIM ImmunoTech Inc (NYSE:AIM) has announced the appointment of Robert Dickey IV, as its chief financial officer (CFO).
Effective April 4, 2022, AIM ImmunoTech said, Dickey will become CFO and current CFO Ellen Lintal will transition to serve as a finance and accounting consultant for the company.
The company noted that Dickey has more than 25 years of experience of C-suite financial leadership for life science and medical device companies, both private and public, ranging from preclinical development to commercial operations and across a variety of disease areas and medical technologies. Earlier in his career, Dickey spent 18 years in investment banking, primarily at Lehman Brothers, with a background split between mergers and acquisitions (M&A) and capital markets transactions.
In a statement, Thomas Equels, the company's chief executive officer said: "On behalf of the team at AIM and our board, I would like to thank Ellen for her many contributions as CFO. AIM is very well positioned for a transformational year and I am thrilled to strengthen our leadership team's depth and breadth with the appointment of Rob as CFO. Over the course of his career, he has built a vast network within Wall Street and industry, and has demonstrated successful execution of financial, licensing, and M&A strategies, all of which we believe will prove to be invaluable to AIM."
READ: AIM ImmunoTech announces positive results from Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
"Rob's successful track record and expertise is perfectly aligned with the vision we share for AIM. I look forward to working closely with Rob and executing on our plan as well as seizing opportunities to propel AIM into its next phase of growth," Equels added.
Dickey commented: "With six ongoing oncology clinical trials with multiple data readouts expected over the next 6-12 months, AIM is entering a pivotal time for the Company and I look forward to leveraging the insight and perspective I've amassed over the course of my career to help capitalize on and create catalytic events to maximize value for all stakeholders."
The company pointed out that Dickey is experienced in all stages of the corporate lifecycle, including start-up and early fundraising, going public, high growth, turnarounds and exit strategies. Career fundraising highlights include raising over $100 million in private company financings, over $200 million for public companies and over $1 billion as an investment banker. His expertise includes public and private financings, M&A, partnering/licensing transactions, project management, overseeing company's finance and accounting functions, and Chapter 11 reorganizations, as well as interactions with Boards, VCs, shareholders and Wall Street.
Dickey currently serves as an advisor to life science companies through Foresite Advisors, LLC which integrates his decades of finance experience with advanced business insights. Prior to becoming an advisor, he served as full-time CFO for Caladrius Biosciences, Tyme Technologies, StemCyte, Locus Pharmaceuticals and Protarga Inc, among others.
He also currently serves on the Board and Audit Committee Chair of Emmaus Life Sciences, a public company with an approved drug for sickle cell disease, on the Board of Angiogenex Inc. a public company out of Memorial Sloan Kettering, Chief Corporate Development Officer of BCI LifeSciences LLC, and part of the Leadership Team at Cell One Partners. Previously, he served on the boards of Sanuthera and Protarga, which he sold to Daiichi Sankyo.
The company noted that Dickey holds an AB from Princeton University and an MBA from The Wharton School, University of Pennsylvania.
AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Contact the author at jon.hopkins@proactiveinvestors.com